WO1997027742B1 - Method of protein production using mitochondrial translation system - Google Patents
Method of protein production using mitochondrial translation systemInfo
- Publication number
- WO1997027742B1 WO1997027742B1 PCT/US1997/000601 US9700601W WO9727742B1 WO 1997027742 B1 WO1997027742 B1 WO 1997027742B1 US 9700601 W US9700601 W US 9700601W WO 9727742 B1 WO9727742 B1 WO 9727742B1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- tissue
- host tissue
- virus
- vitro
- viral antigens
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Abstract
A method of producing viral antigens in vitro by infecting animal organ tissue rich in mitochondria with a virus, including human hepatitis B virus (HBV), and culturing the infected tissue in vitro is disclosed. A method of producing proteins in vitro by transfecting mitochondria-rich animal tissue with a recombinant HBV-based vector and culturing the transfected tissue in a dynamic tissue culture system is disclosed.
Claims
1. A method of producing viral antigens in vitro comprising the steps of: providing a slice of organ tissue of about 2 cm * 2 cm x 260 μm obtained from a nonhumaπ animal to serve as host tissue in in vitro culture, wherein the host tissue is rich in mitochondria; infecting said host tissue in vitro with a virus; culturing said infected host tissue in an in vitro dynamic organ culture system that provides for periodic immersion of said infected host tissue in a tissue culture medium and further provides for gas exchange; allowing said infected tissue to remain in said dynamic organ culture for sufficient time to produce viral antigens; and isolating said viral antigens produced in vitro.
2. The method of Claim 1, wherein the providing step uses host tissue isolated from liver, kidney, pancreas or salivary gland organ tissue.
3. The method of Claim 1, wherein the providing step uses host tissue isolated from a nonhumaπ animal that is a rat, mouse, dog, chicken or frog.
4. The method of Claim 1, wherein the infecting step uses a human virus selected from the group consisting of hepatitis A virus, hepatitis B virus, hepatitis C virus and encephalitis virus.
5. The method of Claim 1, wherein the allowing step produces viral antigens in mitochondria-like organelles in said host tissue in about 24 to about 48 hours.
6. The method of Claim 1, further comprising the step of introducing the isolated viral antigens into an animal to induce an immune response.
7. Viral antigens produced according to the method of Claim 1 and suitable for use in a vaccine.
8. Use of viral antigens produced according to the method of Claim 1 for preparation of a vaccine.
9. A method of producing viral antigens in vitro comprising the steps of: providing a slice of organ tissue of about 2 cm * 2 cm x 260 μm obtained from a nonhuman animal to serve as host tissue in in vitro culture, wherein the host tissue is rich in mitochondria; 1 7
transfecting said host tissue in vitro with a DNA vector comprising a recombinant viral DNA and a DNA sequence to allow expression of the recombinant viral DNA; culturing said transfected host tissue in an in vitro dynamic organ culture system that provides for periodic immersion of said transfected host tissue in a tissue culture medium and further provides for gas exchange; allowing said transfected tissue to remain in the dynamic organ culture for sufficient time to produce viral antigens; and isolating said viral antigens produced in vitro.
10. The method of Claim 9, wherein the providing step uses host tissue isolated from liver, kidney, pancreas or salivary gland organ tissue.
11. The method of Claim 9, wherein the providing step uses host tissue isolated from a nonhuman animal that is a rat, mouse, dog, chicken or frog.
12. The method of Claim 9, wherein the transfecting step uses recombinant viral DNA derived from nucleic acids in hepatitis B virus, hepatitis C virus or a combination thereof.
13. The method of Claim 9, wherein the transfecting step uses recombinant viral DNA derived from nucleic acids in hepatitis B virus and inserted into a human virus DNA sequence coding for a nonstructural viral protein.
14. The method of Claim 9, wherein the allowing step produces viral antigens in mitochondria-like organelles in said host tissue in about 24 to about 48 hours.
15. The method of Claim 9, further comprising the step of infecting or transfecting said host tissue with a helper virus.
16. Viral antigens produced according to the method of Claim 9 and suitable for use in a vaccine.
17. Use of viral antigens produced according to the method of Claim 9 for preparation of a vaccine.
Priority Applications (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP9527666A JP2000504227A (en) | 1996-01-29 | 1997-01-21 | Protein production method using mitochondrial translation system |
| AU18287/97A AU702370B2 (en) | 1996-01-29 | 1997-01-21 | Method of protein production using mitochondrial translation system |
| EP97903809A EP0888046A4 (en) | 1996-01-29 | 1997-01-21 | Method of protein production using mitochondrial translation system |
| US09/124,638 US6100068A (en) | 1997-01-21 | 1998-07-29 | Method of protein production using mitochondrial translation system |
| US10/338,164 US20030099669A1 (en) | 1996-01-29 | 2003-01-06 | Method of protein production using mitochondrial translation system |
| US10/896,363 US20050089532A1 (en) | 1996-01-29 | 2004-07-20 | Method of protein production using mitochondrial translation system |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US1071796P | 1996-01-29 | 1996-01-29 | |
| US60/010,717 | 1996-01-29 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| US09/124,638 Continuation US6100068A (en) | 1996-01-29 | 1998-07-29 | Method of protein production using mitochondrial translation system |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO1997027742A1 WO1997027742A1 (en) | 1997-08-07 |
| WO1997027742B1 true WO1997027742B1 (en) | 1997-09-25 |
Family
ID=21747057
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1997/000601 Ceased WO1997027742A1 (en) | 1996-01-29 | 1997-01-21 | Method of protein production using mitochondrial translation system |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US20030099669A1 (en) |
| EP (1) | EP0888046A4 (en) |
| JP (1) | JP2000504227A (en) |
| CN (1) | CN1162182C (en) |
| AU (1) | AU702370B2 (en) |
| CA (1) | CA2244709A1 (en) |
| RU (1) | RU2201961C2 (en) |
| TW (1) | TWI223665B (en) |
| WO (1) | WO1997027742A1 (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6472200B1 (en) * | 1999-07-23 | 2002-10-29 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Device and method for performing a biological modification of a fluid |
| US8062891B2 (en) | 2003-10-24 | 2011-11-22 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to plants |
| US20090123468A1 (en) | 2003-10-24 | 2009-05-14 | Gencia Corporation | Transducible polypeptides for modifying metabolism |
| JP4838722B2 (en) | 2003-10-24 | 2011-12-14 | ゲンシア コーポレーション | Methods for delivering polynucleotides and compositions for delivery |
| US8133733B2 (en) | 2003-10-24 | 2012-03-13 | Gencia Corporation | Nonviral vectors for delivering polynucleotides to target tissues |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT72015B (en) * | 1979-11-13 | 1982-06-20 | Merck & Co Inc | Process for preparing "invitro" cultures of hepatitis b virus |
| JPS6045535A (en) * | 1983-08-16 | 1985-03-12 | Japan Found Cancer | Manufacturing method for hepatitis B virus vaccine |
| US5645982A (en) * | 1993-08-19 | 1997-07-08 | Systemix, Inc. | Method for screening potential therapeutically effective antiviral agents |
| US6100068A (en) * | 1997-01-21 | 2000-08-08 | Paik-Inje Memorial Institute For Biomedical Science | Method of protein production using mitochondrial translation system |
-
1997
- 1997-01-21 CA CA002244709A patent/CA2244709A1/en not_active Abandoned
- 1997-01-21 RU RU98116217/14A patent/RU2201961C2/en not_active IP Right Cessation
- 1997-01-21 EP EP97903809A patent/EP0888046A4/en not_active Ceased
- 1997-01-21 AU AU18287/97A patent/AU702370B2/en not_active Ceased
- 1997-01-21 JP JP9527666A patent/JP2000504227A/en active Pending
- 1997-01-21 CN CNB971919054A patent/CN1162182C/en not_active Expired - Fee Related
- 1997-01-21 WO PCT/US1997/000601 patent/WO1997027742A1/en not_active Ceased
- 1997-05-16 TW TW086101403A patent/TWI223665B/en active
-
2003
- 2003-01-06 US US10/338,164 patent/US20030099669A1/en not_active Abandoned
-
2004
- 2004-07-20 US US10/896,363 patent/US20050089532A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2008106445A (en) | VIRUS-LIKE BODIES (PARTICLES) AS ANTI-PARAMYXOVIRUS VACCINE | |
| ATE429246T1 (en) | METHOD FOR PRODUCING BIOLOGICAL PRODUCTS IN PROTEIN-FREE CULTURE | |
| NO893149L (en) | PROCEDURE FOR MICROBIOLOGICAL PREPARATION OF HUMANT SERUM ALBUMIN AND OTHER HETEROLOGICAL PROTEINS FROM YOURS. | |
| EP1605052A3 (en) | A method for producing influenza hemagglutinin multivalent vaccines | |
| KR880009130A (en) | Hepatitis B virus surface antigen and hybrid antigen containing the same | |
| ATE423204T1 (en) | PRODUCTION AND PURIFICATION OF HEPATITIS C VIRUS-LIKE PARTICLES | |
| NO20022500L (en) | Process for the preparation of viruses or viral proteins for use in vaccines | |
| CA2272046A1 (en) | Infectious clones of rna viruses and vaccines and diagnostic assays derived thereof | |
| DK0672141T3 (en) | Methods for Preparation of Soluble Oligomeric Proteins | |
| LU91385I2 (en) | CERVARIX - Particle similar to HPV16 virus | |
| ATE70561T1 (en) | METHOD OF CULTURE OF TURKEY RHINOTRACHEITIS VIRUS AND VACCINE PREPARED THEREOF. | |
| ATE130198T1 (en) | PREPARATION OF A VIRUS AND PURIFICATION OF VIRUS COATING PROTEINS FOR VACCINE USE. | |
| CA2302809A1 (en) | Membrane virus host range mutations and their uses as vaccine substrates | |
| RU2000109569A (en) | MUTATIONS OF MULTIPLE MEMBRANE VIRUSES AND THEIR APPLICATION AS SUBSTRATES FOR VACCINES | |
| WO1997027742B1 (en) | Method of protein production using mitochondrial translation system | |
| KR890700030A (en) | Vaccines and diagnostic methods for influenza (Haemophilus influenzae) | |
| KR930702522A (en) | Human body clear layer protein jet blood 3 (ZP3) | |
| KR870006189A (en) | Method of producing polypeptide | |
| ES2061850T3 (en) | RECOMBINANT VIRUSES OF MAREK'S DISEASE, ITS PREPARATION PROCEDURE AND VACCINE. | |
| AU3379693A (en) | Vaccines and diagnostic assays for haemophilus influenzae | |
| ATE299944T1 (en) | SYSTEM FOR PRODUCING PROTEINS | |
| RU98116217A (en) | METHOD FOR PRODUCING PROTEIN USING MITOCHONDRIA TRANSLATION SYSTEM | |
| KR880701285A (en) | Vaccine containing F protein of AIDS virus | |
| RU95113194A (en) | VACCINES, METHOD OF OBTAINING, APPLICATION OF NON-INFECTIOUS SUBVIRUS PARTICLES, VECTORS APPLICATION OF NUCLEIC ACID | |
| US6100068A (en) | Method of protein production using mitochondrial translation system |